DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Foster-Kennedy syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFoster-Kennedy syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for foster-kennedy syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
erythropoietin receptor (EPOR) — EPOR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet nh4drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8VUI · 2.1 Å · ligand AMMONIUM ION (NH4). Experimental structure, not a prediction.
What the evidence adds up to
The 1985 letter to the editor notes that the most common cause of the Foster Kennedy syndrome findings—unilateral optic atrophy and contralateral disc swelling—is bilateral ischaemic optic neuropathy, not the frontal masses originally described by Foster Kennedy. The letter does not report any patient data, treatment, or outcome. The 1991 paper on foster family care and the 2024 paper on Kennedy disease (a different condition caused by CAG repeat expansions in the androgen receptor gene) are not about Foster-Kennedy syndrome and contain no relevant clinical information.
No study in these abstracts tests any drug or intervention for Foster-Kennedy syndrome. No survival rates, response rates, or sample sizes are given. The 1985 letter provides no evidence that any treatment alters the course of the syndrome.
What is missing is any clinical trial, any systematic case series, any data on patient stratification by cause (tumour versus ischaemic optic neuropathy), and any funding for research into the syndrome itself.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Orthopsychiatry · 1991 · 22 citations
Issues in foster family care: Where do we stand?
AbstractAn overview of recent findings about children and families in foster care describes the population, reviews positive and negative results of foster care, and raises such clinical and policy issues as the beneficial outcomes of long-term foster care, the economic crisis for foster parents, and the vulnerability of minority children and families. Implications for research are discussed.
AbstractLetters to the editor should be submitted as an original and two duplicates. They should be typewritten doublespaced on plain bond paper; they will be subject to editing. If they are prepared on a word processor, do not justify the right margin. A copyright transmittal letter signed by all authors must accompany this (see Instructions for Authors). To the Editor. —Thank you for publishing the enjoyable review of the Foster Kennedy syndrome. 1 The authors correctly point out that the signs constituting the Foster Kennedy or pseudo-Foster Kennedy syndromes are unilateral optic atrophy and contralateral disc swelling. While Foster Kennedy described these findings in association with frontal masses, the authors discuss nontumoral causes of this clinical picture and reference three excellent discussions of the subject. 2-4 In addition, the most common cause, by far, of these findings, bilateral ischemic optic neuropathy, deserves specific mention. This condition may be implied within
Stem Cell Research · 2024 · 0 citations · open access
Generation of an induced pluripotent stem cell (iPSC) line (INNDSUi007-A) from a patient with Kennedy disease
AbstractAbnormal trinucleotide CAG repeat expansions in exon 1 of the Androgen Receptor (AR) gene has been identified as the cause of Kennedy disease (KD). We generated and characterized a human induced pluripotent stem cell (iPSC) line from peripheral blood mononuclear cells (PBMC) of a patient with genetically confirmed KD. The pluripotency of these iPSCs was verified by the expression of several pluripotency markers at both RNA and protein levels, as well as their capability to differentiate into all three germ layers.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
